N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide (BioDeep_00000175804)

   

human metabolite blood metabolite


代谢物信息卡片


N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[(2,2,2-trifluoro-1-{4-methanesulphonyl-[1,1-biphenyl]-4-yl}ethyl)amino]pentanimidic acid

化学式: C25H27F4N3O3S (525.170916)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)(CC(C(=O)NC1(CC1)C#N)NC(C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F
InChI: InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)

描述信息

同义名列表

7 个代谢物同义名

N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[(2,2,2-trifluoro-1-{4-methanesulphonyl-[1,1-biphenyl]-4-yl}ethyl)amino]pentanimidic acid; N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[(2,2,2-trifluoro-1-{4-methanesulphonyl-[1,1-biphenyl]-4-yl}ethyl)amino]pentanimidate; N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[(2,2,2-trifluoro-1-{4-methanesulfonyl-[1,1-biphenyl]-4-yl}ethyl)amino]pentanimidate; N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[(2,2,2-trifluoro-1-{4-methanesulfonyl-[1,1-biphenyl]-4-yl}ethyl)amino]pentanamide; N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[2,2,2-trifluoro-1-[4-(4-methylsulphonylphenyl)phenyl]ethyl]amino]pentanamide; N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; odanacatib



数据库引用编号

3 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Patricia J Masarachia, Brenda L Pennypacker, Maureen Pickarski, Kevin R Scott, Gregg A Wesolowski, Susan Y Smith, Rani Samadfam, Jason E Goetzmann, Boyd B Scott, Donald B Kimmel, Le T Duong. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2012 Mar; 27(3):509-23. doi: 10.1002/jbmr.1475. [PMID: 22113859]
  • Li Sun, Sabrina Forni, Michael S Schwartz, Sheila Breidinger, Eric J Woolf. Quantitative determination of odanacatib in human plasma using liquid-liquid extraction followed by liquid chromatography-tandem mass spectrometry analysis. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012 Feb; 885-886(?):15-23. doi: 10.1016/j.jchromb.2011.12.004. [PMID: 22230741]
  • Kong Wah Ng. Potential role of odanacatib in the treatment of osteoporosis. Clinical interventions in aging. 2012; 7(?):235-47. doi: 10.2147/cia.s26729. [PMID: 22866001]
  • Kelem Kassahun, W Cameron Black, Deborah Nicoll-Griffith, Ian McIntosh, Nathalie Chauret, Stephen Day, Elizabeth Rosenberg, Kenneth Koeplinger. Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway. Drug metabolism and disposition: the biological fate of chemicals. 2011 Jun; 39(6):1079-87. doi: 10.1124/dmd.110.037184. [PMID: 21422190]
  • John A Eisman, Henry G Bone, David J Hosking, Michael R McClung, Ian R Reid, Rene Rizzoli, Heinrich Resch, Nadia Verbruggen, Carolyn M Hustad, Carolyn DaSilva, Romana Petrovic, Arthur C Santora, B Avery Ince, Antonio Lombardi. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2011 Feb; 26(2):242-51. doi: 10.1002/jbmr.212. [PMID: 20740685]
  • Laëtitia Michou, Jacques P Brown. Emerging strategies and therapies for treatment of Paget's disease of bone. Drug design, development and therapy. 2011; 5(?):225-39. doi: 10.2147/dddt.s11306. [PMID: 21607019]
  • Anders Bonde Jensen, Christopher Wynne, Guillermo Ramirez, Weili He, Yang Song, Yuliya Berd, Hongwei Wang, Anish Mehta, Antonio Lombardi. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clinical breast cancer. 2010 Dec; 10(6):452-8. doi: 10.3816/cbc.2010.n.059. [PMID: 21147688]
  • S A Stoch, S Zajic, J Stone, D L Miller, K Van Dyck, M J Gutierrez, M De Decker, L Liu, Q Liu, B B Scott, D Panebianco, B Jin, L T Duong, K Gottesdiener, J A Wagner. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clinical pharmacology and therapeutics. 2009 Aug; 86(2):175-82. doi: 10.1038/clpt.2009.60. [PMID: 19421185]